Therapeutic benefits of infrared (810-nm) diode laser macular grid photocoagulation in prophylactic treatment of nonexudative age-related macular degeneration: two-year results of a randomized pilot study.

OBJECTIVE This pilot study collected preliminary information on the effectiveness and safety of infrared (810-nm) diode laser macular grid photocoagulation in patients with nonexudative age-related macular degeneration (AMD). Results from this pilot study were used in designing a larger, multicenter, randomized clinical trial. DESIGN A multicenter, randomized, controlled, clinical trial. PARTICIPANTS A total of 229 eyes of 152 patients with AMD were enrolled in the pilot study. Seventy-five patients with 1 eye eligible (75 eyes) were enrolled in the unilateral arm of the study; 77 patients with both eyes eligible (154 eyes) were enrolled in the bilateral arm of the study. In the unilateral study arm, 32 eyes were randomized to the observation group, 27 eyes were treated with visible endpoint burns, and 16 eyes were treated with invisible endpoint (subthreshold) lesions. In the bilateral study arm, 77 eyes were in the observation group, 36 eyes were treated with visible burns, and 41 eyes were treated with subthreshold (invisible) lesions. INTERVENTION Eyes were treated with infrared (810-nm) diode laser macular grid photocoagulation using either visible burns or subthreshold (invisible) lesions and compared to eyes receiving no treatment. MAIN OUTCOME MEASURES Reduction of drusen, change in visual acuity, and rate of choroidal neovascularization (CNV) membrane formation. RESULTS At 12 months after treatment, 62% of eyes treated with visible burns had a clinically significant reduction in drusen, whereas this proportion (65%) was reached in 18 months for eyes treated with subthreshold lesions. At 24 months' follow-up, treated eyes had a significant reduction in drusen compared to observation eyes (P < 0.0001). Visual acuity was significantly improved in treated eyes at 12, 18, and 24 months compared to observation eyes (P < 0.001). Choroidal neovascularization formation was similar in treated and observation eyes through 24 months' follow-up. Complications included CNV associated with six eyes treated with visible burns and a juxtafoveal laser scar in one eye treated with visible burns. CONCLUSIONS Infrared (810-nm) diode laser macular grid photocoagulation in patients with nonexudative AMD significantly reduces drusen levels (P < 0.0001) and significantly improves visual acuity (P < 0.001) when either visible endpoint burns or subthreshold endpoint lesions are used. Complications were fewer using subthreshold endpoint lesions. A larger, multicenter, prospective clinical trial with longer follow-up is needed to determine the efficacy of treatment in reducing the rate of CNV formation. Data from this clinical pilot study have been used to design the Prophylactic Treatment of AMD Trial (PTAMD), a multicenter, randomized, prospective clinical trial currently in progress comparing subthreshold (invisible) treatment to observation in eyes with nonexudative AMD.

[1]  R. Guymer,et al.  Laser treatment in subjects with high-risk clinical features of age-related macular degeneration. Posterior pole appearance and retinal function. , 1997, Archives of ophthalmology.

[2]  A C Bird,et al.  Bilateral macular drusen in age-related macular degeneration. Prognosis and risk factors. , 1994, Ophthalmology.

[3]  M. Figueroa,et al.  LASER PHOTOCOAGULATION TO TREAT MACULAR SOFT DRUSEN IN AGE‐RELATED MACULAR DEGENERATION , 1994, Retina.

[4]  P. Wetzig.  Treatment of drusen-related aging macular degeneration by photocoagulation. , 1988, Transactions of the American Ophthalmological Society.

[5]  C. Frennesson,et al.  Effects of argon (green) laser treatment of soft drusen in early age-related maculopathy: a 6 month prospective study. , 1995, The British journal of ophthalmology.

[6]  Mark S. Blumenkranz,et al.  Laser treatment in eyes with large drusen. Short-term effects seen in a pilot randomized clinical trial. Choroidal Neovascularization Prevention Trial Research Group. , 1998, Ophthalmology.

[7]  C. A. Wilson,et al.  Blood-retinal barrier breakdown caused by diode vs argon laser endophotocoagulation. , 1992, Archives of ophthalmology.

[8]  J. Norris,et al.  Prophylactic photocoagulation of the fellow eye in exudative senile maculopathy. A preliminary report. , 1979, Modern problems in ophthalmology.

[9]  S. Fine,et al.  Prognosis of patients with bilateral macular drusen. , 1984, Ophthalmology.

[10]  N. Bressler,et al.  Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group. , 1990, Archives of ophthalmology.

[11]  J. Pulido,et al.  Tissue effects of subclinical diode laser treatment of the retina. , 1998, Archives of ophthalmology.

[12]  J. Gass.  Photocoagulation of macular lesions. , 1971, Transactions - American Academy of Ophthalmology and Otolaryngology. American Academy of Ophthalmology and Otolaryngology.

[13]  C. Frennesson,et al.  Prophylactic laser treatment in early age related maculopathy reduced the incidence of exudative complications , 1998, The British journal of ophthalmology.

[14]  A. Bird,et al.  The risk of fellow eye visual loss with unilateral retinal pigment epithelial tears. , 1989, American journal of ophthalmology.

[15]  J. Sigelman.  Foveal drusen resorption one year after perifoveal laser photocoagulation. , 1991, Ophthalmology.

[16]  M. Gillies,et al.  Prophylactic perifoveal laser treatment of soft drusen. , 1996, Australian and New Zealand journal of ophthalmology.

[17]  H. Little,et al.  A pilot randomized controlled study on the effect of laser photocoagulation of confluent soft macular drusen. , 1997, Ophthalmology.

[18]  Judith Alexander,et al.  Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Macular Photocoagulation Study Group. , 1997, Archives of ophthalmology.